Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Aug;185(2):464-465.
doi: 10.1111/bjd.20138. Epub 2021 May 31.

Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®

B Chrétien  1 , C Dolladille  1 , J Alexandre  1 , S Fedrizzi  1 , V Lelong-Boulouard  1 , J C Lambert  2 , E Ezine  3
Affiliations
Observational Study

Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®

B Chrétien et al. Br J Dermatol. 2021 Aug.
No abstract available

PubMed Disclaimer

References

    1. Agache I, Song Y, Posso M et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021; 76:45-58.
    1. Willsmore ZN, Woolf RT, Hughes C et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol 2019; 181:1068-70.
    1. de Wijs LEM, van der Waa JD, de Jong PHP, Hijnen DJ. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol 2020; 45:262-3.
    1. Hooper J, Weeks B, Dreyfus DH. Safety and efficacy of dupilumab in adult patients with a history of eczema herpeticum. J Allergy Clin Immunol 2018; 141 (Suppl. 1):AB230.
    1. Sears AV, Woolf RT, Gribaleva E et al. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated. Br J Dermatol 2021; 184:755-7.

MeSH terms

Substances

LinkOut - more resources